Last reviewed · How we verify

Bactroban — Competitive Intelligence Brief

Bactroban (MUPIROCIN) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: RNA Synthetase Inhibitor Antibacterial. Area: Immunology.

marketed RNA Synthetase Inhibitor Antibacterial Isoleucine--tRNA ligase, cytoplasmic Immunology Small molecule Live · refreshed every 30 min

Target snapshot

Bactroban (MUPIROCIN) — GSK. Bactroban works by inhibiting the production of essential proteins in bacteria, preventing them from reproducing and causing infection.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Bactroban TARGET MUPIROCIN GSK marketed RNA Synthetase Inhibitor Antibacterial Isoleucine--tRNA ligase, cytoplasmic 1987-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (RNA Synthetase Inhibitor Antibacterial class)

  1. GSK · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Bactroban — Competitive Intelligence Brief. https://druglandscape.com/ci/mupirocin. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: